Business Wire

MERZ-AESTHETICS

21.3.2024 09:01:28 CET | Business Wire | Press release

Share
Merz Aesthetics Sponsors Symposium on Global Beauty Landscape and Presents New Insights Around Regenerative Aesthetics at the 2024 Aesthetic and Anti-Aging Medicine World Congress (AMWC)

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, is presenting new data for its product portfolio in addition to perspectives on medical aesthetics trends at the 2024 Aesthetic and Anti-Aging Medicine World Congress. AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine. Participants can attend live in Monaco or tune in virtually beginning March 27 through March 29, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321775430/en/

Merz Aesthetics’ programming includes a sponsored symposium on March 28 from 14:00 - 16:00 CET, Beauty Without Borders: Aesthetics Across Continents, moderated by Dr. Sabrina Fabi, featuring commentary from Dr. Kate Goldie, Dr. Siew Tuck Wah, Dr. Rolf Bartsch and Dr. Rossana Vasconcelos. During the session, the group will discuss the multifaceted landscape of beauty and aging around the world, the nuances and variances of aging concerns among different patient populations and the recommended techniques and products.

“Each year, AMWC allows us the opportunity to connect and collaborate with peers from around the world and provides a forum to showcase our research and advancements in medical aesthetics,” said Terri Phillips, MD, Chief Medical Affairs Officer, Merz Aesthetics. “We’re excited to engage in scientific exchange, foster new connections and discuss innovations within our portfolio, in addition to sharing insights from the evolving field of regenerative aesthetics.”

“At Merz Aesthetics, we aim to provide the best experience possible for our health care professionals and their patients,” said Gonzalo Mibelli, President, EMEA, Merz Aesthetics. “I’m looking forward to presenting our latest data and honoring the commitment we’ve made to our customers to meet their evolving needs.”

In addition to the symposium, Merz Aesthetics is presenting five e-posters for the first time. The abstracts will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts. Following are the highlighted e-posters:

  • Long-term Duration and Safety of CaHA(+)-CMC for the Treatment of Jawline – Jeremy B. Green, MD, Roberta Del Campo, MD, Alan J. Durkin, MD, David K. Funt, MD, Nicole Nasrallah, MS, Keith Martinez, PhD, Amir Moradi, MD
  • Tissue Integration of Hyaluronic Acid-Containing Dermal Fillers: Automated Approach Using a Human Skin Model Under Optimal Tension – Kay Marquardt, PhD, Christian Hartmann, PhD, Michael Conneely, PhD, Robyn Hickerson, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
  • Stimulation of Elastin Neogenesis by Micro-Focused Ultrasound (MFU-V) – Kay Marquardt, PhD, Christian Hartmann, PhD, Flora Wegener, PhD, Nils Warfving, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
  • Consensus Agreements on Regenerative Aesthetics: Terminology, Goals, and Strategies – Dr. Kate Goldie, Dr. Greg Chernoff, Dr. Niamh Corduff, Dr. Owen Davies, Dr. Jani van Loghem, Dr. Bianca Viscomi
  • Micro-focused Ultrasound with Visualization and Aesthetic Outcomes: A Systematic Review and Meta-analysis of Clinical Studies – Dr. Sabrina Guillen Fabi, Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Julia Sevi, Dr. Julieta Spada, Dr. Vasanop Vachiramon, Dr. Rossana Vasconcelos, Dr. Siew Tuck Wah

Merz Aesthetics will be located at Booth J1 on Level 1.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321775430/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 11:01:00 CET | Press release

HIGHLIGHTS:Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today.An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership.His appointment further strengthens the Board's scientific and strategic expertise as Chiesi advances its commitment to delivering innovative solutions for patients. Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of

Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 10:30:00 CET | Press release

Madrid-based appointment will focus on expanding the company’s presence across Southern Europe and developing opportunities in new markets Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expandin

Alushibe Holding Group to Bring 12 Global F&B Brands to Libya by 202829.10.2026 09:00:00 CET | Press release

Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 Alushibe Holding Group today announced plans to bring 12 international food-and-beverage brands to Libya by 2028 through its Retail & Destinations division, beginning with an exclusive master franchise agreement with MADO, the Turkish ice-cream and patisserie house founded in 1850. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029822317/en/ Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 – (Photo: AETOSWire) Signed in Kahramanmaraş on 13 October 2026 by Ahmed Gadalla, Founder and Chairman of Alushibe Holding Group, and Mehmet Sait Kanbur, Chairman of MADO, the agreement grants Alushibe exclusive rights to develop and opera

U.S. Bancorp Announces New U.S. Bancorp Global Funds Brand29.10.2026 09:00:00 CET | Press release

The platform also introduces its first offshore liquidity fund, domiciled in Ireland U.S. Bancorp today announced its new fund platform, U.S. Bancorp Global Funds, and its first offering, an offshore liquidity fund domiciled in Ireland, the U.S. Bancorp Liquidity – USD Treasury CNAV Fund. U.S. Bancorp Global Funds was created to support U.S. Bancorp’s growing international presence. It establishes a framework for future investment offerings and reflects U.S. Bancorp’s expanding presence in global markets. Investment products offered under the brand are established through U.S. Bancorp Global Funds ICAV, an Ireland-domiciled UCITS umbrella fund structure. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is the first offering introduced under the new brand. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is designed for investors outside the United States seeking to preserve capital while accessing a U.S. Treasury-focused liquidity solution within a regulated offshore structure. D

Element Biosciences Launches AVITI Dx™, Bringing CE-Marked IVD Sequencing to Ten EU Countries29.10.2026 09:00:00 CET | Press release

Integrated sequencing, reagents, and software bring IVDR-compliant sequencing capabilities to European clinical laboratories, with additional global markets planned to follow Element Biosciences, Inc. today announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union's In Vitro Diagnostic Regulation (EU IVDR). AVITI Dx integrates Element’s AVITI™ sequencing system, dedicated reagents, and software designed to meet applicable IVDR requirements and support regulated clinical laboratory workflows. The system is launching commercially in ten EU countries: the Netherlands, Germany, France, Italy, Spain, Austria, the Czech Republic, Latvia, Romania, and Poland, with additional markets planned through a phased approach. Developed and manufactured under Element's ISO 13485-certified quality management system, AVITI Dx is a Class A IVD sequencing system supported by IVDR-compliant reagents and software. Built o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye